深圳市易瑞生物技术股份有限公司2025年第三季度报告

Core Points - The company ensures that the content of the quarterly report is true, accurate, and complete, with no false records or misleading statements [2][8] - The third-quarter financial report has not been audited [3][7] Financial Data - The company does not require retrospective adjustments or restatements of previous annual accounting data [3] - There are no non-recurring profit and loss items applicable for the reporting period [3][4] - The company confirms that there are no changes in major accounting data and financial indicators that require explanation [5] Shareholder Information - The total number of ordinary shareholders and the number of preferred shareholders have changed due to stock issuance and other reasons [5] - There are no changes in the top ten shareholders or the top ten unrestricted circulating shareholders due to stock lending activities [5][6] Board Meeting - The company's board meeting was held on October 27, 2025, with all seven directors present, complying with legal and regulatory requirements [9][10] - The board approved the third-quarter report and the appointment of a new member to the strategic committee [10][11]